ROCKET ALERT: Bragar Eagel & Squire, P.C. is Investigating Rocket Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Rocket Pharmaceuticals, Inc. due to allegations of fiduciary duty breaches by the board of directors, following a class action complaint related to misleading statements about the company's clinical trial safety [2][8]. Group 1: Legal Investigation - The investigation is focused on long-term stockholders of Rocket Pharmaceuticals who held securities between February 27, 2025, and May 26, 2025 [2]. - The class action complaint was filed on June 11, 2025, concerning the company's failure to disclose critical information about the safety of its RP-A501 clinical trial [2][8]. Group 2: Clinical Trial Issues - The complaint alleges that Rocket provided overly positive statements while concealing material adverse facts regarding the safety of RP-A501, including the risk of Serious Adverse Events (SAEs) [8]. - On May 27, 2025, Rocket announced that the FDA placed a clinical hold on the RP-A501 Phase 2 pivotal study after a patient suffered a SAE, which included death, following undisclosed amendments to the trial protocol [8]. Group 3: Stock Price Impact - Following the announcement of the clinical hold, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% in just one trading day [8].